Mirum Pharmaceuticals Raises Revenue Guidance, Secures Reimbursement in Japan, and Expands Product Portfolio

Mirum Pharmaceuticals' strong commercial performance and strategic initiatives have driven a Buy rating from H.C. Wainwright analyst Swayampakula Ramakanth. The price target was raised to $80.00, based on factors including revenue growth of flagship product LIVMARLI, reimbursement in Japan, a US tablet launch, and growth in the bile acid portfolio.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has seen its stock surge following the release of its second quarter (Q2) 2025 financial results, which significantly exceeded analyst expectations. The biopharmaceutical company reported a Q2 loss of $0.12 per share, beating estimates of a $0.33 loss by $0.21 [1]. Revenue reached $127.8 million, a 64% increase from the same period last year, far surpassing the consensus estimate of $107.4 million [1].

The company's flagship product, Livmarli, saw remarkable 87% year-over-year (YoY) growth in net product sales, reaching $88.2 million, while Bile Acid Medicines generated $39.6 million, up 30% from the second quarter of 2024 [1]. These strong performances prompted Mirum to raise its full-year revenue guidance to between $490 million and $510 million [1].

The company's chief executive officer, Chris Peetz, attributed the success to the performance of its International business and U.S. PFIC launch, stating that "the momentum we are seeing with Livmarli globally reinforces our belief that the medicine will reach and help more patients than we initially projected, allowing us to raise guidance with confidence" [1].

Mirum's stock price has been positively impacted by these results, with the share price rising by 8.6% following the announcement [1]. The company's strong financial position, with unrestricted cash, cash equivalents, and investments totaling $321.7 million as of June 30, 2025, also supports its growth prospects [1].

In response to these positive developments, H.C. Wainwright analyst Swayampakula Ramakanth has issued a Buy rating for Mirum Pharmaceuticals, raising the price target to $80.00. The analyst cited factors including revenue growth of the flagship product Livmarli, reimbursement in Japan, a US tablet launch, and growth in the bile acid portfolio [2].

References:
[1] https://www.investing.com/news/earnings/mirum-pharmaceuticals-soars-as-revenue-crushes-estimates-93CH-4174634
[2] https://www.marketwatch.com/story/mirum-pharmaceuticals-gains-after-2q-loss-narrows-revenue-rises-96f0de71